Disagreement between bedside and laboratory activated partial thromboplastin time and international normalized ratio for various novel anticoagulants

Blood Coagulation and Fibrinolysis

Volumn 12, Issue 7, 2001, Pages 583-591

  Kemme, Michiel J B ^a   Faaij, R A ^a   Schoemaker, R C ^a   Kluft, C ^b   Meijer, P ^b   Cohen, A F ^a   Burggraaf, J ^a  

^a CENTRE FOR HUMAN DRUG RESEARCH   (Netherlands)

^b TNO   (Netherlands)

Author keywords

Activated partial thromboplastin time; Bedside monitor; International normalized ratio; Prothrombin time

Indexed keywords

ANTICOAGULANT AGENT; FONDAPARINUX; HEPARIN; NAPSAGATRAN; RECOMBINANT TISSUE FACTOR PATHWAY INHIBITOR; WARFARIN;

ADULT; ARTICLE; BLOOD CLOTTING PARAMETERS; BLOOD SAMPLING; CLINICAL ARTICLE; HUMAN; INTERMETHOD COMPARISON; LABORATORY TEST; OUTPATIENT CARE; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTHROMBIN TIME; THROMBOEMBOLISM;

ANTICOAGULANTS; ANTITHROMBINS; DRUG MONITORING; FALSE NEGATIVE REACTIONS; FALSE POSITIVE REACTIONS; FIBRINOLYTIC AGENTS; HEPARIN; HUMANS; LABORATORIES; NAPHTHALENES; OLIGOSACCHARIDES; PARTIAL THROMBOPLASTIN TIME; PIPERIDINES; POINT-OF-CARE SYSTEMS; REPRODUCIBILITY OF RESULTS; WARFARIN;

EID: 0034748741     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001721-200110000-00012     Document Type: Article

References (32)

1. Effect of heparin on whole blood activated partial thromboplastin using a portable, whole blood coagulation monitor
2. Evaluation of bedside prothrombin time and activated partial thromboplastin time measurement by coagulation analyzer Coagu Check Plus in various clinical settings
3. Bedside monitoring of heparin therapy: Comparison of activated clotting time to activated partial thromboplastin time
4. New bedside test for monitoring anticoagulation during hemodialysis
5. Comparison of bedside coagulation monitoring tests with standard laboratory tests in patients after cardiac surgery
6. Intraoperative measurement of activated partial thromboplastin time and prothrombin time by a portable laser photometer in patients following cardiopulmonary bypass
7. Multicenter evaluation of a new capillary blood prothrombin time monitoring system
8. A comparison of INRs determined with a whole blood prothrombin time device and two international reference preparations for thromboplastin
9. Evaluation of a portable prothrombin time monitor for home use by patients who require long-term oral anticoagulant therapy
10. A novel whole blood capillary technic for measuring the prothrombin time
11. Accuracy of laboratory and portable monitor International Normalized Ratio Determinations. Comparison with a criterion standard
12. Accuracy and precision of a portable anticoagulation monitor in a clinical setting
13. Evaluation of the Ciba Corning Biotrach 512 coagulation monitor for the control of oral anticoagulation
14. Are capillary whole blood coagulation monitors suitable for the control of oral anticoagulant treatment by the international normalized ratio?
15. A comparison of point-of-care instruments designed for monitoring oral anticoagulation with standard laboratory methods
16. Home monitoring of warfarin therapy in children with a whole blood prothrombin time monitor
17. Inhibition of clot-bound and free (fluid-phase thrombin) by a novel synthetic thrombin inhibitor (Ro 46-6240), recombinant hirudin and heparin in human plasma
18. Biochemical and pharmacologic rationale for the development of a synthetic heparin pentasaccharide
19. Biochemical and pharmacological properties of SANORG 34006, a potent and long-acting synthetic pentasaccharide
20. Statistical methods for assessing agreement between two methods of clinical measurement
21. Comparing methods of measurement: Why plotting difference against standard method is misleading
22. The reliability of activated partial thromboplastin time methods and the relationship to lipid composition and ultrastructure
23. Variability in heparin sensitivity of APTT reagents
24. Monitoring heparin therapy by the activated partial thromboplasin time - The effect of pre-analytical conditions
25. The effect of platelet factor 4 (PF4) on assays of plasma heparin
26. Effect of concentration of trisodium citrate anticoagulant on calculation of the International Normalised Ratio and the International Sensitivity Index of thromboplastin
27. Standardization of prothrombin time for laboratory control of oral anticoagulant therapy
28. The international normalized ratio. A guide to understanding and correcting its problems
29. Behaviour of factors II, VII, IX and X during long treatment with coumarin
30. A method to determine the optimal intensity of oral anticoagulant therapy
31. Heparin and low-molecular-weight heparin: Mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety
32. Index of individuality and utility of population based reference range